文献速递系统性红斑狼疮其他结缔组织病

乌帕替尼或艾沙布替尼单药及联合治疗系统性红斑狼疮的疗效与安全性:2期随机对照试验

Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2024-08-07

48周2期SLEek研究(NCT03978520)将341例中重度活动性系统性红斑狼疮成人随机分配至艾沙布替尼60mg联合乌帕替尼30mg(ABBV-599高剂量)、艾沙布替尼60mg联合乌帕替尼15mg(ABBV-599低剂量)、艾沙布替尼60mg单药、乌帕替尼30mg单药或安慰剂每日一次。计划期中分析显示ABBV-599低剂量和艾沙布替尼单药缺乏疗效而终止(无安全性问题)。乌帕替尼组54.8%(P=0.028)和ABBV-599高剂量组48.5%(P=0.081)达到主要终点者多于安慰剂组37.3%;两组SRI-4、BICLA、LLDAS应答率在第24和48周均高于安慰剂, flares减少且至首次flare时间延迟,未见新安全性信号。

要点

  • 乌帕替尼30mg单药组54.8%达到主要终点,显著高于安慰剂组37.3%(P=0.028)。
  • ABBV-599高剂量组48.5%达到主要终点,与安慰剂组37.3%比较P=0.081。
  • ABBV-599低剂量和艾沙布替尼单药因计划期中分析显示缺乏疗效而终止,无安全性问题。

核心结论

  • 乌帕替尼30mg单药或与艾沙布替尼联合(ABBV-599高剂量)在48周内显著改善SLE疾病活动度并减少flare,且耐受性良好。

研究设计与样本

  • 48周2期SLEek研究(NCT03978520)将341例中重度活动性SLE成人按1:1:1:1:1随机分配至艾沙布替尼60mg联合乌帕替尼30mg每日一次(ABBV-599高剂量)、艾沙布替尼60mg联合乌帕替尼15mg每日一次(ABBV-599低剂量)、艾沙布替尼60mg每日一次、乌帕替尼30mg每日一次或安慰剂每日一次。

主要发现

  • 达到主要终点(第24周同时实现SRI-4和糖皮质激素剂量≤10mg每日一次)的比例:乌帕替尼组54.8%(P=0.028)、ABBV-599高剂量组48.5%(P=0.081) vs 安慰剂组37.3%。
  • 乌帕替尼和ABBV-599高剂量组在第24周和第48周的SRI-4、BICLA和LLDAS应答率均高于安慰剂组。
  • 与安慰剂相比,乌帕替尼和ABBV-599高剂量均减少flare,并显著延迟至第48周的首次flare时间。
  • 除乌帕替尼或艾沙布替尼既往报告的安全性信号外,未观察到新的安全性信号。
  • 计划期中分析显示ABBV-599低剂量和艾沙布替尼单药缺乏疗效(无安全性问题),随后终止这两组。

关键数值与推荐

  • 主要终点为第24周同时达到SRI-4和糖皮质激素剂量≤10mg每日一次的患者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The 48-week, phase 2 SLEek study (NCT03978520) evaluated the efficacy and safety of upadacitinib (JAK inhibitor) and elsubrutinib (BTK inhibitor) alone or in combination (ABBV-599) in adults with moderately to severely active systemic lupus erythematosus (SLE). METHODS: Patients were randomized 1:1:1:1:1 to elsubrutinib 60 mg and upadacitinib 30 mg once daily (ABBV-599 high dose), elsubrutinib 60 mg and upadacitinib 15 mg once daily (ABBV-599 low dose), elsubrutinib 60 mg once daily (QD), upadacitinib 30 mg QD, or placebo QD. The primary endpoint was the proportion of patients achieving both Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and glucocorticoid dose ≤10 mg QD at week 24. Additional assessments through week 48 included British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) and Lupus Low Disease Activity State (LLDAS) responses, number of flares, time to first flare, and adverse events. RESULTS: The study enrolled 341 patients. The ABBV-599 low dose and elsubrutinib arms were discontinued after a planned interim analysis showed lack of efficacy (no safety concerns). More patients achieved the primary endpoint with upadacitinib (54.8%; P = 0.028) and ABBV-599 high dose (48.5%; P = 0.081) versus placebo (37.3%). SRI-4, BICLA, and LLDAS response rates were higher for both upadacitinib and ABBV-599 high dose versus placebo at weeks 24 and 48. Flares were reduced, and time to first flare through week 48 was substantially delayed with both upadacitinib and ABBV-599 high dose versus placebo. No new safety signals were observed beyond those previously reported for upadacitinib or elsubrutinib. CONCLUSION: Upadacitinib 30 mg alone or in combination with elsubrutinib (ABBV-599 high dose) demonstrated significant improvements in SLE disease activity and reduced flares and were well tolerated through 48 weeks.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Merrill JT, Tanaka Y, D'Cruz D, et al. Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial. Arthritis Rheumatol. 2024. PMID: 38923871. doi:10.1002/art.42926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。